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Globally the demographic trend is moving towards a society with an increasing percentage of
older people. The increase in life expectancy has been a major achievement. However, this brings
the challenge for pharmaceutical development to meet the specific healthcare and medication
needs of older people. The goal of drug therapy should be towards maintaining the quality of life
in later years of life. The drug product development should not only focus on efficacy, safety and
quality of drug therapy but also aim to improve patient acceptability and compliance. Hence an
individualized approach should be considered at the point of pharmaceutical design, by tailoring
the design according to the changes in drug delivery barriers due to advanced age and
administration related needs of older patients. Correspondingly, the European Medicines Agency
(EMA) has published the concept paper on the need for consideration of quality aspects of
medicines for older people in order to provide an overview of aspects requiring special
consideration in the pharmaceutical development. The EMA Quality Working Party is currently
developing a further reflection paper which is expected to follow a similar pattern of process as
that used for the EMA`s guideline on the pharmaceutical development of medicines for
paediatric use.
The Special Issue on Geriatric Drug Therapy begins with papers defining the older patient in terms
of the independent/ safe use of pharmaceutical drug products and describing the clinical
characteristics, physiology, psychology, physical functioning in this population. The Special Issue
also covers the perspective of academia, the pharmaceutical industry and regulatory agencies in
relation to pharmaceutical development for older people. We also present papers which focus on
age-related physiological differences and associated formulation approaches for delivering drug
therapies to older people via different routes of administration. In addition, the Special Issue has
a viewpoint article on the pharmaceutical strategies towards optimising polypharmacy in older
people. Studies on the acceptability of medicines in older adults are outlined in three research
articles, two of which focus on the swallowability of oral medicine and one which investigates the
ease of opening of pharmaceutical packaging by seniors. Finally, medicines optimisation in older
patients is discussed in the context of dementia, an age-related disease which is fast becoming a
global concern.
We would like to express our thanks to all the authors who have highlighted the key themes in
the field of age-related medicines development and use. Special thanks go to Prof Sandy Florence
for suggesting a Special Issue on Geriatric Drug Therapy which is very timely in view of the growing
interest in this topic. Ageing research is expanding and there is potential for advancements in
pharmaceutical sciences which will be able to drive the development of drug products responding to
the age-related changes on the barriers to drug delivery. The collaborative discussion between
academia, pharmaceutical industry, healthcare professionals, medicinal regulatory agencies and
patients` representatives will enable ongoing development of patient-centric geriatric drug
therapies.
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